Kansai Rosai Hospital
Amagasaki, Hyōgo, Japan
NCT Number: NCT01947478
The purpose of this trial is to assess the safety and efficacy of MDT-2113 for the interventional treatment of de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and the proximal popliteal artery (PPA) as compared to treatment with standard percutaneous transluminal angioplasty (PTA).
Looking for future studies?
Notify Me20 year–85 year
All sexes
Interventional
Not applicable
Amagasaki, Hyōgo, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
Time frame: 12 month
Primary patency is defined as freedom from clinically-driven target lesion revascularization (TLR) and freedom from restenosis as determined by duplex ultrasound (DUS)
Time frame: 12 month
Freedom from device- and procedure-related death through 30 days post-procedure, and freedom from target limb major amputation and clinically-driven target vessel revascularization (TVR)
Medtronic Endovascular
Industry
Randomized Trial of MDT-2113 Drug-Eluting Balloon (DEB) vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery
Acronym: MDT-2113 SFA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03844724
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT01566461
Arterial Occlusive Diseases, Arteriosclerosis
Fremont, California, United States
View Trial DetailsNCT05734157
Femoral Artery Occlusion, Femoral Artery Stenosis
Ollioules, France
View Trial DetailsNCT01412541
Femoral Artery Occlusion, Femoral Artery Stenosis
Los Angeles, California, United States
View Trial Details